Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 203-212

  Kiyozuka, Yasuhiko ^a   Yamamoto, Daigo ^a   Yang, Jihong ^a   Uemura, Yoshiko ^a   Senzaki, Hideto ^a   Adachi, Susumu ^b   Tsubura, Airo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Anticancer agent; Chemosensitivity; Chemotherapy; Cisplatin; CPT 11; Cyclophosphamide; Doxorubicin; Etoposide; Ifomide; Ovarian cancer; Paclitaxel; Resistance; Telomerase; Telomerase RNA; Telomere; Telomere length

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; PACLITAXEL; TELOMERASE;

ARTICLE; CALORIMETRY; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; RNA TRANSCRIPTION; SOUTHERN BLOTTING; TELOMERE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CALORIMETRY; CAMPTOTHECIN; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TELOMERASE; TELOMERE; TUMOR CELLS, CULTURED;

EID: 0034070275     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Zakian VA: Telomeres: Beginning to understand the end. Science 270: 1601-1607, 1995.
2. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
3. Hurley CB and Villeponteau B: Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 5: 249-255, 1995.
4. Kim NW, Piatysek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
5. Greider CW: Telomerase biochemistry and regulation. In: Telomeres. (Blackburn KH and Greider CW, eds). Cold Spring Harbor (NY). Cold Spring Harbor Laboratory Press, 1995. pp35-68.
6. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B: The RNA component of human telomerase. Science 269: 1236-1241, 1995.
7. Blasco MA, Funk W, Villeponteau B and Greider CW: Functional characterization and developmental regulation of mouse telomerase RNA. Science 269: 1267-1270, 1995.
8. Harrington L, McPhail T, Mar V, Zhou W, Arruda I and Robinson MO: A mammalian telomerase-associated protein. Science 275: 973-477, 1997.
9. Nakayama J, Saito M, Nakamura H, Matsuura A and Ishikawa F: TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 88: 875-884, 1997.
10. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V and Cech TR: Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276: 561-567, 1997.
11. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Biejersbergen RL, Davidoff MJ, Liu O, Bacchetti S, Haber DA and Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalisation. Cell 90: 785-795, 1997.
12. Holt SE, Wright WE and Shay JW: Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16: 2932-2939, 1996.
13. Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T and Tahara E: Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1: 1245-1251, 1995.
14. Hiyama E, Gollahou L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA and Shay JW: Telomerase activity in human breast tumors. J Natl Cancer Inst 88: 116-122, 1996.
15. Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW and Gazdar AF: Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 57: 2373-2377, 1997.
16. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K, Shay JW, Matsuura Y and Yokoyama T: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 57: 326-331, 1997.
17. Wam M, Li W-Z, Duggan BD, Felix JC, Zhao Y and Dubeau L: Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst 89: 437-441, 1997.
18. Kyo S, Takakura M, Kohama T and Inoue M: Telomerase activity in human endometrium. Cancer Res 57: 610-614, 1997.
19. Sallinen P, Miettinen H, Sallinen SL, Haapasalo H, Helin H and Kononen J: Increased expression of telomerase RNA component is associated with increased cell proliferation in human astrocytomas. Am J Pathology 150: 1159-1164, 1997.
20. Zhang W, Piatyszek A, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, Wright WE and Shay JW: Telomerase activity in human acute myelogeneous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 2: 799-803, 1996.
21. Bestilny LJ, Brown CB, Miura Y, Robertson LD and Riabowol KT: Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res 56: 3796-3802, 1996.
22. Morin GB: Is teomerase a universal cancer target? J Natl Cancer Inst 87: 859-861, 1995.
23. Parkinson EK: Do telomerase antagonists reresent a novel anticancer strategy? Br J Cancer 73: 1-4, 1996.
24. Strahl C and Blackburn EH: Effect of reverse transcriptase inhibition on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16: 53-65, 1996.
25. Norton JC, Piatyszek MA, Wright WE, Shay JW and Corey DR: Inhibition of human telomerase activity by peptide nucleic-acids. Nature Biotechnol 14: 615-619, 1996.
26. Burget AM, Double JA and Newell DR: Inhibition of telomerase actitvity by cisplatin in human testicular cancer cells. Fur J Cancer 33: 638-644, 1997.
27. Ku WC, Cheng AJ and Wang TCV: Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cacner cells in culture. Biochem Biophys Res Commu 241: 730-736, 1997.
28. Kikuchi Y, Miyauchi M, Kizawa I, Oomori K and Kato K: Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer I 77: 1181-1185, 1986.
29. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418, 1987.
30. Yamada T, Ueda M, Otsuki Y, Ueki M and Sugimoto O: Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary. Gynecol Oncol 40: 118-128, 1991.
31. Morimitsu Y, Yano H and Kojiro M : Morphologic characteristics, proliferation and tumor marker expression of two human ovarian carcinoma cell lines in three-dimentional culture. Gynecol Oncol 48: 155-164, 1993.
32. Harwerth IM, Wels W, Schlegel J, Muller M and Hynes NE: Monoclonal antibodies directed to the erhB-2 receptor inhibit in vitro tumour cell growth. Br J cancer 68: 1140-1145, 1993.
33. Imai S, Kiyozuka Y, Maeda H, Noda T and Hosick HL: Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology 47: 177-184, 1990.
34. Yoshida M, Kiyozuka Y, Noda T, Imai S and Ichijo M: Establishment and characterization of human cell line derived from mucinous cystadenocarcinoma of ovary. J Jpn Soc Clin Cytol 32: 1-8, 1993.
35. Kiyozuka Y, Nishimura H, Iwanaga N, Yakushiji M, Ito K, Nakano S, Tamori N, Adachi S, Noda T and Imai S: Establishment and characterization of human ovarian fibrosarcoma cell line and its sensitivity to anticancer agents. Acta Obst Gynaec Jpn 44: 461-468, 1992.
36. Imamura K, Kiyozuka Y, Nishimura H and Yakushiji M: Novel germ cell tumor cell line established from a testicular feminization syndrome. Oncol Rep 2: 17-25, 1995.
37. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987.
38. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chroloform extraxtion. Anal Biochem 162: 156-159, 1987.
39. Chirguin JM, Przybyla AE, MacDonald RJ and Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299, 1979.
40. Kipling D, Wilson HE, Thomson IJ and Cooke HJ: YAC cloning Mus musculus telomeric DNA; physical, genetic, in situ and STS markers for the distal telomere of chromosome 10. Hum Mol Genet 4: 1007-1014, 1945.
41. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K and Tsubura A: Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: Correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 18: 1465-1462, 1998.
42. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, Kleinman HK and Schnaper W: Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in murine model. Circulation 91: 755-762, 1995.
43. Counter CM, Hirte HW, Bacchetti S and Harley CB: Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91: 2900-2904, 1994.
44. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK and Allshire RC: Telomere reduction in human colorectal carcinoma and with ageing. Nature 346: 866-868, 1990.
45. Rhyu M: Telomeres, telomerase, immortality. J Natl Cancer Inst 87: 884-894, 1995.
46. Murakami J, Nagai N, Ohama K, Tahara H and Ide T: Telomerase activity in ovarian tumors. Cancer 80; 1085-1092, 1997.
47. Gorham H, Yoshida K, Sugino G, Marsh G, Manek S, Charnock M, Tarin D and Goodison S: Telomerase activity in human gynecological malignancies. J Clin Pathol 50: 501-504, 1997.
48. Wan M, Li WZ, Duggan BD, Felix JC, Zhao Y and Dubeau L: Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst 19: 437-441, 1997.
49. Avilion AA, Piatyzek MA, Gupta J Shay JW, Bacchetti S and Greider CW: Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 56: 645-650, 1996.
50. Winick M, Coscia A and Noble A: Cellular growth in human placenta. I. Normal placental growth. Pediatrics 39: 248-251, 1967.
51. Wright WE, Piatyszek MA, Rainey WE, Byrd W and Shay JW: Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18: 173-179, 1996.
52. Hiyama K, Hirai Y, Kyoizumu S, Akiyama M, Hiyama E, Piatyzek MA and Shay JW: Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155: 3711-3715, 1995.
53. Bryan TM and Reddel RR: Telomere dynamics and telomerase activity in in vitro immortalized cells. Eur J Cancer 33: 767-773, 1997.
54. Takakura M, Kyo S, Kanaya T, Tanaka M and Inoue M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 58: 1558-1561, 1998.
55. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P and de Lange T: A human telomeric protein. Science 270: 1663-1667, 1995.
56. Wright WE and Shay JW: Time, telomerase and tumours: Is cellular senescence more than an anticancer mechanism? Trends Cell Biol 5: 293-297, 1995.
57. Bayne RAL, Broccoli D, Taggart MH, Thompson EJ, Farr CJ and Cooke HJ: Sandwiching of a gene with 12 kb of a functional telomere and alpha-satellite does not result in silencing. Hum Mol Genet 3: 539-546, 1994.
58. Lane DP: p53, gurdian of the genome. Nature 358: 15-16, 1992.
59. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
60. Bond JA, Wyllie FS and Wynford-Thomas D: Escape from senescence in human diploid fibroblasts induced directly by mutant p53. Oncogene 9: 1885-1889, 1994.
61. Wynford-Thomas D, Bond JA, Wylie FS and Jones CJ: Does telomere shortning drive selection for p53 mutation in human cancer? Mol Carcinogen 12: 119-123, 1995.
62. Sherman SE and Lippard SJ: Structural aspects of platinum anticancer drug-interactions with DNA. Chem Rev 87: 1153-1181, 1987.
63. Norton JC, Piatyszek MA, Wright WE, Shay JW and Corey DR: Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotechnol 14: 615-619, 1996.
64. Kiyozuka Y, Nishimura H, Murakami F, Imamura K, Adachi S, Noda T, Itoh K, Itani Y, Tamori N, Imai S and Yakushiji M: In vitro chemosensitizing effect in ovarian cancer of low-dose continuous exposure to etoposide combined with cisplatin. J Jpn Soc Cancer Ther 29: 876-887, 1994.